MedTrace Logo

Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

NCT05665374 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2026-05-15

No results posted yet for this study

Summary

To understand the incidence of ADRs of Calquence capsules 100 mg (acalabrutinib) used in patients with previously untreated chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma (SLL)) in the post-marketing setting under actual use

Conditions

  • Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)

Sponsors & Collaborators

Principal Investigators

  • Toshimitsu Tokimoto · AstraZeneca KK

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-19
Primary Completion
2025-08-20
Completion
2025-08-20

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05665374 on ClinicalTrials.gov